BiomX (PHGE) Non-Current Deffered Revenue (2022 - 2023)
BiomX (PHGE) posted Non-Current Deffered Revenue of $2.0 million for Q4 2023, little changed sequentially from $2.0 million in Q3 2023, and little changed YoY from $2.0 million in Q4 2022.
BiomX (PHGE) Non-Current Deffered Revenue (2022 - 2023) Analysis & Trends
BiomX has reported Non-Current Deffered Revenue for 2 years, with the latest figure at $2.0 million in Q4 2023.
- Quarterly Non-Current Deffered Revenue changed 0.0% year-over-year to $2.0 million in Q4 2023, while the trailing twelve-month figure through Dec 2023 was $2.0 million (changed 0.0% YoY) and the FY2023 annual result came in at $2.0 million, changed 0.0% from the prior year.
- Non-Current Deffered Revenue was little changed at $2.0 million in Q4 2023 per PHGE's latest filing, from $2.0 million in the prior quarter.
- Over five years, Non-Current Deffered Revenue peaked at $2.0 million in Q4 2022 and troughed at $2.0 million in Q4 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 220.40 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 147.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | BiomX | 351,774.34 | -816,225.66 | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 1.98 Mn |
| Sep 30, 2023 | 1.98 Mn |
| Jun 30, 2023 | 1.98 Mn |
| Mar 31, 2023 | 1.98 Mn |
| Dec 31, 2022 | 1.98 Mn |